<DOC>
	<DOCNO>NCT01739491</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness extend bendamustine treatment chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>A Study Safety Effectiveness Bendamustine Hydrochloride Adult Filipino Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This Phase IV , open label ( people know identity intervention ) , multi-center , observational ( scientific study make clear easy understanding cause effect relationship ) study bendamustine . The study duration 24 Weeks coincide 4 weeks-6 cycle bendamustine treatment . The study run three year , enroll 10 percent patient would use product , requirement Philippine Food Drug Administration ( FDA ) . Approximately fifty patient enrol study . Safety evaluation include adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination monitor throughout study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Adult Filipino patient chronic lymphocytic leukemia Patients cytologicallydiagnosed chronic lymphocytic leukaemia ( symptomatic Binet stage B C ) fludarabine combination chemotherapy appropriate World health organization performance Status 0 , 1 , 2 Needtotreat criterion Bcell chronic lymphocytic leukemia Had receive previous treatment cytotoxic drug Had history second malignancy ( except cure basal cell carcinoma cure cervical cancer ) Concomitant illnesses overt heart failure , cardiomyopathy , myocardial infarction within last 6 month , severe uncontrolled diabetes mellitus , severe uncontrolled hypertension , active infection require systemic antibiotic treatment investigational drug study within 30 day prior selection Patients severe renal hepatic impairment Patients severe bone marrow suppression severe blood count alteration Pregnant woman lactate mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Bendamustine hydrochloride</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Filipino</keyword>
</DOC>